Biological Therapy Industry in the United States: Market Research Reports, Statistics and Analysis

Merck Kgaa - Company Report For Year 2012

Company Report: Biological Therapy In The United States For Year ...

... From funding. The doc/nist will review research using human embryonic stem cell lines that it supports and conducts in accordance with the common rule and nist implementing procedures, as appropriate ...

Company Report: Stem Cell In The United States For Year 2013

... A few. stem cells have the potential to overcome these limitations and act as a more effective form of treatment for a myocardial infarction. A stem cell is classified as an undifferentiated, self ...

Stemcells Inc. - Company Report For Year 2013

... Biotechnology company. Gfap and nestin are proteins that are co-expressed by certain key cells found in the human central nervous system. Each patent claims a cell culture of undifferentiated gfap+ nestin+ cells ...

Company Report: Biological Therapy In The United States And Franc ...

Company Report: Stem Cell In The United States For Year 2013

Biological Therapy Market Trends In The United States And Canada

... On human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (gm-csf), an immune-stimulatory cytokine. We continue to see promise with gvax, Said ...

Biological Therapy Market Trends In The United States And Canada

... On human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (gm-csf), an immune-stimulatory cytokine. We continue to see promise with gvax, Said ...

U.s. Biological Therapy Business

... Advani et al. Bruton tyrosine kinase ibrutinib (pci-32765) has significant activity in patients with relapsed/refractory b-cell malignancies. Journal of clinical oncology (31): 88-94 byrd, ash 2012 ...